Amplification of CDK4 and MDM2 in malignant melanoma

Cancer Statistics, 2004

Jemal, A., Tiwari, R. C., Murray, T., Ghafoor, A., Samuels, A., Ward, E., Feuer, E. J., & Thun, M. J. (2004) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.54.1.8 · Cited by 3,984 · see citing works

Inactivation of the apoptosis effector Apaf-1 in malignant melanoma

Soengas, M. S., Capodieci, P., Polsky, D., Mora, J., Esteller, M., Opitz-Araya, X., McCombie, W. R., Herman, J. G., Gerald, W. L., Lazebnik, Y. A., et al. (2001) · Nature · doi:10.1038/35051606 · Cited by 965 · see citing works

Classifying Melanocytic Tumors Based on DNA Copy Number Changes

Bastian, B. C., Olshen, A. B., LeBoit, P. E., & Pinkel, D. (2003) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)63536-5 · Cited by 460 · see citing works

Coamplification of the CDK4 gene with MDM2 and GLI in human sarcomas.

Khatib, Z. A., Matsushime, H., Valentine, M. B., Shapiro, D. N., Sherr, C. J., & Look, A. T. (1993) · PubMed · Cited by 339 · see citing works

Genetics of melanoma predisposition

Hayward, N. K. (2003) · Oncogene · doi:10.1038/sj.onc.1206445 · Cited by 321 · see citing works

The genetics of malignant melanoma: lessons from mouse and man

Chin, L. (2003) · Nature reviews. Cancer · doi:10.1038/nrc1145 · Cited by 300 · see citing works

Alterations of the Tumor Suppressor Genes CDKN2A (p16), p14, CDKN2B (p15), and CDKN2C (p18) in Atypical and Anaplastic Meningiomas

Boström, J. P., Meyer‐Puttlitz, B., Wolter, M., Blaschke, B., Weber, R. G., Lichter, P., Ichimura, K., Collins, V. P., & Reifenberger, G. (2001) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)61737-3 · Cited by 277 · see citing works

Gene amplifications characterize acral melanoma and permit the detection of occult tumor cells in the surrounding skin.

Bastian, B. C., Kashani–Sabet, M., Hamm, H., Godfrey, T. E., Moore, D. H., Bröcker, E.-B., LeBoit, P. E., & Pinkel, D. (2000) · PubMed · Cited by 245 · see citing works

Alternative and aberrant splicing of MDM2 mRNA in human cancer

Bartel, F., Taubert, H. W., & Harris, L. C. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00091-0 · Cited by 196 · see citing works

Quantification of MYCN, DDX1, and NAG Gene Copy Number in Neuroblastoma Using a Real-Time Quantitative PCR Assay

Preter, K. D., Speleman, F., Combaret, V., Lunec, J., Laureys, G., Eussen, B. H. J., Francotte, N., Julian Board, Pearson, A. D. J., Paepe, A. D., et al. (2002) · Modern Pathology · doi:10.1038/modpathol.3880508 · Cited by 181 · see citing works

Refined mapping of 12q13-q15 amplicons in human malignant gliomas suggests CDK4/SAS and MDM2 as independent amplification targets.

Reifenberger, G., Ichimura, K., REIFENBERGER, J., ELKAHLOUN, A. G., Meltzer, P. S., & Collins, V. P. (1996) · PubMed · Cited by 175 · see citing works

Dual Inactivation of RB and p53 Pathways in RAS-Induced Melanomas

Bardeesy, N., Bastian, B. C., Hezel, A., Pinkel, D., DePinho, R. A., & Chin, L. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.6.2144-2153.2001 · Cited by 166 · see citing works

Invasive melanoma in Cdk4-targeted mice

Sotillo, R., García, J. F., Ortega, S., Martín‐Broto, J., Dubus, P. R., Barbacid, M., & Malumbres, M. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.241338598 · Cited by 164 · see citing works

Amplification pattern of 12q13–q15 genes (MDM2, CDK4, GLI) in urinary bladder cancer

Simon, R., Struckmann, K., Schraml, P., Wagner, U., Forster, T., Moch, H., Fijan, A., Bruderer, J., Wilber, K., Mihatsch, M. J., et al. (2002) · Oncogene · doi:10.1038/sj.onc.1205304 · Cited by 157 · see citing works

Gene amplification in human gliomas

Collins, V. P. (1995) · Glia · doi:10.1002/glia.440150309 · Cited by 149 · see citing works

HDM2 protein overexpression, but not gene amplification, is related to tumorigenesis of cutaneous melanoma.

Polsky, D., Bastian, B. C., Hazan, C., Melzer, K., Pack, J., Houghton, A., BUSAM, K. J., Cordon‐Cardo, C., & Osman, I. (2001) · PubMed · Cited by 120 · see citing works

Components of the Rb pathway are critical targets of UV mutagenesis in a murine melanoma model

Kannan, K., Sharpless, N. E., Xu, J., O’Hagan, R. C., Bosenberg, M., & Chin, L. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0336397100 · Cited by 116 · see citing works

Evaluation of MDM2 and CDK4 amplification by real‐time PCR on paraffin wax‐embedded material: a potential tool for the diagnosis of atypical lipomatous tumours/well‐differentiated liposarcomas

Hostein, I., Pelmus, M., Aurias, A., Pédeutour, F., Mathoulin‐Pélissier, S., & Coindre, J.-M. (2003) · The Journal of Pathology · doi:10.1002/path.1495 · Cited by 115 · see citing works

Both products of the mouse Ink4a/Arf locus suppress melanoma formation in vivo

Sharpless, N. E., Kannan, K., Xu, J., Bosenberg, M., & Chin, L. (2003) · Oncogene · doi:10.1038/sj.onc.1206809 · Cited by 97 · see citing works

CDK4 is a probable target gene in a novel amplicon at 12q13.3–q14.1 in lung cancer

Wikman, H., Nymark, P. E. H., Väyrynen, A., Jarmalaitė, S., Kallioniemi, A. H., Salmenkivi, K., Vainio-Siukola, K. J., Husgafvel‐Pursiainen, K., Knuutila, S., Wolf, M., et al. (2004) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20122 · Cited by 84 · see citing works

Genetic status of cell cycle regulators in squamous cell carcinoma of the oesophagus: the CDKN2A (p16INK4a and p14ARF ) and p53 genes are major targets for inactivation

Smeds, J. (2002) · Carcinogenesis · doi:10.1093/carcin/23.4.645 · Cited by 68 · see citing works

Untitled work

Berner (1996) · doi:10.1002/(sici)1098-2264(199612)17:4

Regulating the p53 pathway: in vitro hypotheses, in vivo veritas

Toledo, F., & Wahl, G. M. (2006) · Nature reviews. Cancer · doi:10.1038/nrc2012 · Cited by 1,286 · see citing works

Malignant melanoma: genetics and therapeutics in the genomic eraPreprint

Chin, L., Garraway, L. A., & Fisher, D. E. (2006) · Genes & Development · doi:10.1101/gad.1437206 · Cited by 509 · see citing works

Melanoma: from mutations to medicine

Tsao, H., Chin, L., Garraway, L. A., & Fisher, D. E. (2012) · Genes & Development · doi:10.1101/gad.191999.112 · Cited by 496 · see citing works

From genes to drugs: targeted strategies for melanoma

Flaherty, K. T., Hodi, F. S., & Fisher, D. E. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3218 · Cited by 351 · see citing works

MDM4 is a key therapeutic target in cutaneous melanoma

Gembarska, A., Luciani, F., Fedele, C., Russell, E. A., Dewaele, M., Villar, S., Zwolinska, A., Haupt, S., de Lange, J., Yip, D., et al. (2012) · Nature Medicine · doi:10.1038/nm.2863 · Cited by 327 · see citing works

Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E–mutated melanomas

Smalley, K. S. M., Lioni, M., Palma, M. D., Xiao, M., Desai, B. M., Egyházi, S., Hansson, J., Wu, H., King, A. J., Belle, P. A. V., et al. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0431 · Cited by 310 · see citing works

The melanomas: a synthesis of epidemiological, clinical, histopathological, genetic, and biological aspects, supporting distinct subtypes, causal pathways, and cells of origin

Whiteman, D. C., Pavan, W. J., & Bastian, B. C. (2011) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2011.00880.x · Cited by 272 · see citing works

Integrative genome analysis reveals an oncomir/oncogene cluster regulating glioblastoma survivorship

Kim, H., Huang, W., Jiang, X., Pennicooke, B. H., Park, P. J., & Johnson, M. D. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0909896107 · Cited by 239 · see citing works

Genome-Wide Loss of Heterozygosity and Copy Number Analysis in Melanoma Using High-Density Single-Nucleotide Polymorphism Arrays

Stark, M. S., & Hayward, N. K. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4152 · Cited by 238 · see citing works

Pathways and therapeutic targets in melanoma

Shtivelman, E., Davies, M. A., Hwu, P., Yang, J. C.-H., Lotem, M., Oren, M., Flaherty, K. T., & Fisher, D. E. (2014) · Oncotarget · doi:10.18632/oncotarget.1892 · Cited by 219 · see citing works

Melanoma subtypes: genomic profiles, prognostic molecular markers and therapeutic possibilities

Rabbie, R., Ferguson, P. M., Molina‐Aguilar, C., Adams, D. J., & Robles‐Espinoza, C. D. (2018) · The Journal of Pathology · doi:10.1002/path.5213 · Cited by 217 · see citing works

The genomic landscape of cutaneous melanoma

Zhang, T., Dutton‐Regester, K., Brown, K. M., & Hayward, N. K. (2016) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12459 · Cited by 173 · see citing works

Restoring p53 Function in Human Melanoma Cells by Inhibiting MDM2 and Cyclin B1/CDK1-Phosphorylated Nuclear iASPP

Lu, M. M., Breyssens, H., Salter, V., Zhong, S., Hu, Y., Baer, C., Ratnayaka, I., Sullivan, A., Brown, N. R., Endicott, J., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.03.013 · Cited by 166 · see citing works

Melanocytic nevus-like hyperplasia and melanoma in transgenic BRAFV600E mice

Goel, V., Ibrahim, N., Jiang, G., Singhal, M., Fee, S., Flotte, T. J., Westmoreland, S. V., Haluska, F. S., Hinds, P. W., & Haluska, F. G. (2009) · Oncogene · doi:10.1038/onc.2009.95 · Cited by 165 · see citing works

The genome and epigenome of malignant melanoma

Dahl, C., & Guldberg, P. (2007) · Apmis · doi:10.1111/j.1600-0463.2007.apm_855.xml.x · Cited by 161 · see citing works

NRAS mutant melanoma: Towards better therapies

Randic, T., Kozar, I., Margue, C., Utikal, J. S., & Kreis, S. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102238 · Cited by 159 · see citing works

Targeting MDM2-p53 Interaction for Cancer Therapy: Are We There Yet?

Nag, S. A., Zhang, X., Srivenugopal, K. S., Wang, M.-H., Wang, W., & Zhang, R. (2014) · Current Medicinal Chemistry · doi:10.2174/09298673113206660325 · Cited by 151 · see citing works

Effects of mutations in Wnt/β-catenin, hedgehog, Notch and PI3K pathways on GSK-3 activity—Diverse effects on cell growth, metabolism and cancer

McCubrey, J. A., Rakus, D., Gizak, A., Steelman, L. S., Abrams, S. L., Lertpiriyapong, K., Fitzgerald, T. L., Yang, L. V., Montalto, G., Cervello, M., et al. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2016.09.004 · Cited by 149 · see citing works

Molecular Pathogenesis of Cutaneous Melanocytic Neoplasms

Ibrahim, N., & Haluska, F. G. (2008) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev.pathol.3.121806.151541 · Cited by 137 · see citing works

Molecular drivers of cellular metabolic reprogramming in melanoma

Abildgaard, C., & Guldberg, P. (2015) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2014.12.007 · Cited by 132 · see citing works

Melanoma: From Melanocyte to Genetic Alterations and Clinical Options

Bertolotto, C. (2013) · Scientifica · doi:10.1155/2013/635203 · Cited by 130 · see citing works

Clinical translation of nuclear export inhibitors in cancer

Senapedis, W. T., Baloglu, E., & Landesman, Y. (2014) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2014.04.005 · Cited by 126 · see citing works

Characterization of the 12q15 <i>MDM2</i> and 12q13‐14 <i>CDK4</i> amplicons and clinical correlations in osteosarcoma

Mejia‐Guerrero, S., Quejada, M., Gokgoz, N., Gill, M., Parkes, R. K., Wunder, J. S., & Andrulis, I. L. (2010) · Genes, Chromosomes and Cancer · doi:10.1002/gcc.20761 · Cited by 120 · see citing works

Optimal Management of Metastatic Melanoma: Current Strategies and Future Directions

Batus, M., Waheed, S., Ruby, C. E., Petersen, L. F., Bines, S. D., & Kaufman, H. L. (2013) · American Journal of Clinical Dermatology · doi:10.1007/s40257-013-0025-9 · Cited by 116 · see citing works

miR-579-3p controls melanoma progression and resistance to target therapy

Fattore, L., Mancini, R., Acunzo, M., Romano, G., Laganà, A., Pisanu, M. E., Malpicci, D., Madonna, G., Mallardo, D., Capone, M., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1607753113 · Cited by 111 · see citing works

Targeting Oncogenic Drivers and the Immune System in Melanoma

McArthur, G. A., & Ribas, A. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.5568 · Cited by 105 · see citing works

Ki67 expression levels are a better marker of reduced melanoma growth following MEK inhibitor treatment than phospho-ERK levels

Smalley, K. S. M., Contractor, R., Haass, N. K., Lee, J. T., Nathanson, K. L., Medina, C. A., Flaherty, K. T., & Herlyn, M. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603596 · Cited by 102 · see citing works

Central chondrosarcoma progression is associated with pRb pathway alterations: CDK4 down‐regulation and p16 overexpression inhibit cell growth in vitro

Schrage, Y. M., Lam, S., Jochemsen, A. G., Cleton-Jansen, A., Taminiau, A. H. M., Hogendoorn, P. C. W., & Bovée, J. V. M. G. (2008) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2008.00406.x · Cited by 101 · see citing works

Identification of a Novel Subgroup of Melanomas with KIT/Cyclin-Dependent Kinase-4 Overexpression

Smalley, K. S. M., Contractor, R., Nguyen, T. K., Xiao, M., Edwards, R. H., Muthusamy, V., King, A. J., Flaherty, K. T., Bosenberg, M., Herlyn, M., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0235 · Cited by 99 · see citing works

p53 Rescue through HDM2 Antagonism Suppresses Melanoma Growth and Potentiates MEK Inhibition

Ji, Z., Njauw, C.-N. J., Taylor, M., Neel, V., Flaherty, K. T., & Tsao, H. (2011) · Journal of Investigative Dermatology · doi:10.1038/jid.2011.313 · Cited by 74 · see citing works

Whole‐exome sequencing of oral mucosal melanoma reveals mutational profile and therapeutic targets

Lyu, J., Song, Z., Chen, J., Shepard, M. J., Song, H., Ren, G., Li, Z., Guo, W., Zhuang, Z., & Shi, Y. (2017) · The Journal of Pathology · doi:10.1002/path.5017 · Cited by 74 · see citing works

Rational drug design, synthesis, and biological evaluation of novel chiral tetrahydronaphthalene-fused spirooxindole as MDM2-CDK4 dual inhibitor against glioblastoma

Wang, B., Peng, F., Huang, W., Zhou, J., Zhang, N., Sheng, J., Haruehanroengra, P., He, G., & Han, B. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2019.12.013 · Cited by 73 · see citing works

Genetics and epigenetics of cutaneous malignant melanoma: A concert out of tune

van den Hurk, K., Niessen, H. E. C., Veeck, J., van den Oord, J. J., Steensel, M. A. M. V., Hausen, A. Z., van Engeland, M., & Winnepenninckx, V. J. L. (2012) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2012.03.011 · Cited by 69 · see citing works

P53 in skin cancer: From a master player to a privileged target for prevention and therapy

Loureiro, J. B., Abrantes, A. M., Oliveira, P. A., & Saraiva, L. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188438 · Cited by 69 · see citing works

Activation of p53 with Nutlin-3a radiosensitizes lung cancer cells via enhancing radiation-induced premature senescence

Luo, H., Yount, C. L., Lang, H., Yang, A., Riemer, E. C., Lyons, K., Vanek, K. N., Silvestri, G. A., Schulte, B. A., & Wang, G. Y. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.04.017 · Cited by 65 · see citing works

Micro RNA ‐206 induces G 1 arrest in melanoma by inhibition of CDK 4 and C yclin D

Georgantas, R. W., Streicher, K. L., Luo, X., Greenlees, L. M., Zhu, W., Liu, Z., Brohawn, P. Z., Morehouse, C. A., Higgs, B. W., Richman, L. K., et al. (2013) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12200 · Cited by 66 · see citing works

Specificity, selection and significance of gene amplifications in cancer

Myllykangas, S., Böhling, T., & Knuutila, S. (2006) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2006.10.005 · Cited by 66 · see citing works

CRM1 and BRAF Inhibition Synergize and Induce Tumor Regression in BRAF-Mutant Melanoma

Fragomeni, R. A. S., Chung, H. W., Landesman, Y., Senapedis, W. T., Saint‐Martin, J., Tsao, H., Flaherty, K. T., Shacham, S., Kauffman, M. G., & Cusack, J. C. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-1171 · Cited by 65 · see citing works

p63 is an alternative p53 repressor in melanoma that confers chemoresistance and a poor prognosis

Matin, R., Chikh, A., Chong, S. L. P., Mesher, D., Graf, M., Sanzà, P., Senatore, V., Scatolini, M., Moretti, F., Leigh, I. M., et al. (2013) · The Journal of Experimental Medicine · doi:10.1084/jem.20121439 · Cited by 65 · see citing works

MicroRNA-34b/c suppresses uveal melanoma cell proliferation and migration through multiple targets.

Dong, F., & Lou, D. (2012) · PubMed Central · Cited by 62 · see citing works

GAB2 Amplifications Refine Molecular Classification of Melanoma

Chernoff, K. A., Bordone, L. A., Horst, B. A. J., Simon, K., Twadell, W. S., Lee, K., Cohen, J. A., Wang, S., Silvers, D. N., Brunner, G., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0280 · Cited by 59 · see citing works

Melanoma: Clinical Features and Genomic InsightsPreprint

Hawryluk, E. B., & Tsao, H. (2014) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a015388 · Cited by 55 · see citing works

<i>MDM2</i> Gene Amplification Is Correlated to Tumor Progression but not to the Presence of SNP309 or <i>TP53</i> Mutational Status in Primary Colorectal Cancers

Forslund, A., Zeng, Z., Qin, L.-X., Rosenberg, S., Ndubuisi, M., Pincas, H., Gerald, W., Notterman, D. A., Barany, F., & Paty, P. B. (2008) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-07-0239 · Cited by 54 · see citing works

Ultraviolet light and melanoma

Craig, S., Earnshaw, C. H., & Virós, A. (2018) · The Journal of Pathology · doi:10.1002/path.5039 · Cited by 54 · see citing works

Oncogenic B-RafV600E Induces Spindle Abnormalities, Supernumerary Centrosomes, and Aneuploidy in Human Melanocytic Cells

Cui, Y., Borysova, M. K., Johnson, J., & Guadagno, T. M. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-1491 · Cited by 53 · see citing works

Mapping genetic alterations causing chemoresistance in cancer: identifying the roads by tracking the drivers

Lønning, P. E., & Knappskog, S. (2013) · Oncogene · doi:10.1038/onc.2013.48 · Cited by 53 · see citing works

Alterations of cell cycle genes in cancer: unmasking the role of cancer stem cells

Çağlar, H. O., & Avcı, Ç. B. (2020) · Molecular Biology Reports · doi:10.1007/s11033-020-05341-6 · Cited by 49 · see citing works

A CDKN2A Mutation in Familial Melanoma that Abrogates Binding of p16INK4a to CDK4 but not CDK6

Jones, R., Ruas, M., Gregory, F. J., Moulin, S., Delia, D., Manoukian, S., Rowe, J., Brookes, S., & Peters, G. G. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1528 · Cited by 49 · see citing works

Limited genomic heterogeneity of circulating melanoma cells in advanced stage patients

Velasco, C. R., Li, J., Luttgen, M. S., Kolatkar, A. R., Kendall, J., Flores, E. I., Topp, Z. Z., Samlowski, W. E., McClay, E. F., Bethel, K. J., et al. (2015) · Physical Biology · doi:10.1088/1478-3975/12/1/016008 · Cited by 48 · see citing works

Aberrant Expression of Posterior HOX Genes in Well Differentiated Histotypes of Thyroid Cancers

Cantile, M., Scognamiglio, G., Sala, L. L., Mantia, E. L., Scaramuzza, V., Valentino, E., Tatangelo, F., Losito, S., Pezzullo, L., Chiofalo, M. G., et al. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms141121727 · Cited by 43 · see citing works

Increased HOX C13 expression in metastatic melanoma progression

Cantile, M., Scognamiglio, G., Anniciello, A., Farina, M., Gentilcore, G., Santonastaso, C., Fulciniti, F., Cillo, C., Franco, R., Ascierto, P. A., et al. (2012) · Journal of Translational Medicine · doi:10.1186/1479-5876-10-91 · Cited by 43 · see citing works

HEDGEHOG/GLI-E2F1 axis modulates iASPP expression and function and regulates melanoma cell growth

Pandolfi, S., Montagnani, V., Lapucci, A., & Stecca, B. A. (2015) · Cell Death and Differentiation · doi:10.1038/cdd.2015.56 · Cited by 42 · see citing works

Reactivation of p53 as therapeutic intervention for malignant melanoma

Jochemsen, A. G. (2013) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000033 · Cited by 42 · see citing works

Restoring the tumour suppressive function of p53 as a parallel strategy in melanoma therapy

Lu, M. M., Miller, P. F., & Lü, X. (2014) · FEBS Letters · doi:10.1016/j.febslet.2014.05.008 · Cited by 42 · see citing works

Activation of AKT and nuclear accumulation of wild type TP53 and MDM2 in anal squamous cell carcinoma

Patel, H., Polanco-Echeverry, G. M., Segditsas, S., Volikos, E., Reed, A. E. M., Lai, C. S. L., Guenther, T., Zaitoun, A. M., Sieber, O. M., Ilyas, M., et al. (2007) · International Journal of Cancer · doi:10.1002/ijc.23028 · Cited by 42 · see citing works

CDK4 inhibition diminishes p53 activation by MDM2 antagonists

Sriraman, A., Dickmanns, A., Najafova, Z., Johnsen, S. A., & Dobbelstein, M. (2018) · Cell Death &amp; Disease · doi:10.1038/s41419-018-0968-0 · Cited by 40 · see citing works

SKI knockdown inhibits human melanoma tumor growth in vivo

Chen, D., Lin, Q., Box, N. F., Roop, D. R., Ishii, S., Matsuzaki, K., Fan, T., Hornyak, T. J., Reed, J. A., Stavnezer, E., et al. (2009) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2009.00603.x · Cited by 38 · see citing works

Understanding the Biology of Melanoma and Therapeutic Implications

Sullivan, R. J., & Fisher, D. E. (2014) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2014.02.007 · Cited by 37 · see citing works

New Strategies in Metastatic Melanoma: Oncogene-Defined Taxonomy Leads to Therapeutic Advances

Flaherty, K. T., & Fisher, D. E. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2612 · Cited by 36 · see citing works

Biological challenges of BRAF inhibitor therapy

Puzanov, I. J., Burnett, P., & Flaherty, K. T. (2011) · Molecular Oncology · doi:10.1016/j.molonc.2011.01.005 · Cited by 36 · see citing works

BRAF Inhibitors and Melanoma

Flaherty, K. T. (2011) · The Cancer Journal · doi:10.1097/ppo.0b013e31823e5357 · Cited by 36 · see citing works

Dominant Effects of Δ40p53 on p53 Function and Melanoma Cell Fate

Takahashi, R., Markovic, S. N., & Scrable, H. J. (2013) · Journal of Investigative Dermatology · doi:10.1038/jid.2013.391 · Cited by 36 · see citing works

In vivo corrosion, tumor outcome, and microarray gene expression for two types of muscle-implanted tungsten alloys

Schuster, B. E., Roszell, L. E., Murr, L. E., Ramirez, D. A., Demaree, J. D., Klotz, B. R., Rosencrance, A. B., Dennis, W. E., Bao, W., Perkins, E. J., et al. (2012) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2012.08.025 · Cited by 35 · see citing works

Resistance to transforming growth factor -mediated tumor suppression in melanoma: are multiple mechanisms in place?

Lasfar, A., & Cohen-Solal, K. (2010) · Carcinogenesis · doi:10.1093/carcin/bgq155 · Cited by 34 · see citing works

A MAPK/miR-29 Axis Suppresses Melanoma by Targeting MAFG and MYBL2

Vera, O., Bok, I., Jasani, N., Nakamura, K., Xu, X., Mecozzi, N., Angarita, A. M., Wang, K., Tsai, K. Y., & Karreth, F. A. (2021) · Cancers · doi:10.3390/cancers13061408 · Cited by 31 · see citing works

Genetic Mutations Involved in Melanoma: A Summary of Our Current Understanding

High, W. A., & Robinson, W. A. (2007) · Advances in Dermatology · doi:10.1016/j.yadr.2007.07.009 · Cited by 32 · see citing works

Identification of TFG (TRK‐fused gene) as a putative metastatic melanoma tumor suppressor gene

Dutton‐Regester, K., Aoude, L. G., Nancarrow, D. J., Stark, M. S., O’Connor, L., Lanagan, C., Pupo, G. M., Tembe, V., Carter, C. D., OʼRourke, M. G. E., et al. (2012) · Genes Chromosomes and Cancer · doi:10.1002/gcc.21932 · Cited by 31 · see citing works

Novel Candidate Key Drivers in the Integrative Network of Genes, MicroRNAs, Methylations, and Copy Number Variations in Squamous Cell Lung Carcinoma

Huang, T., Jing, Y., & Cai, Y. (2015) · BioMed Research International · doi:10.1155/2015/358125 · Cited by 28 · see citing works

DNA repair and cell cycle checkpoint defects as drivers and therapeutic targets in melanoma

Pavey, S. J., Spoerri, L., Haass, N. K., & Gabrielli, B. G. (2013) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12136 · Cited by 27 · see citing works

Cyclin‐dependent kinases as therapeutic targets in melanoma

Miller, D. M., & Flaherty, K. T. (2014) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12211 · Cited by 27 · see citing works

Unclassified sclerosing malignant melanomas with AKAP9-BRAF gene fusion: a report of two cases and review of BRAF fusions in melanocytic tumors

Perron, É., Pissaloux, D., Neub, A., Hohl, D., Tartar, M. D., Mortier, L., Alberti, L., & de la Fouchardière, A. (2018) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-017-2290-0 · Cited by 27 · see citing works

Fine needle aspiration biopsy diagnosis of dedifferentiated liposarcoma: Cytomorphology and MDM2 amplification by FISH

Al-Maghraby, H., Khalbuss, W. E., Rao, U. N. M., Cieply, K. M., Đačić, S., & Monaco, S. E. (2010) · CytoJournal · doi:10.4103/1742-6413.62257 · Cited by 24 · see citing works

Discovery of Novel Naphthylphenylketone and Naphthylphenylamine Derivatives as Cell Division Cycle 25B (CDC25B) Phosphatase Inhibitors: Design, Synthesis, Inhibition Mechanism, and in Vitro Efficacy against Melanoma Cell Lines

Cerchia, C., Nasso, R., Mori, M., Villa, S., Gelain, A., Capasso, A., Aliotta, F., Simonetti, M., Rullo, R., Masullo, M., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00632 · Cited by 24 · see citing works

Amplification of CDK4 and MDM2: a detailed study of a high-risk neuroblastoma subgroup

Martinez‐Monleon, A., Kryh, H., Gaarder, J., Berbegall, A. P., Javanmardi, N., Djos, A., Ussowicz, M., Taschner‐Mandl, S., Ambros, I. M., Øra, I., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-16455-1 · Cited by 23 · see citing works

Mdm2-SNP309 polymorphism in prostate cancer: no evidence for association with increased risk or histopathological tumour characteristics

Stoehr, R., Hitzenbichler, F., Kneitz, B., Hammerschmied, C. G., Bürger, M., Tannapfel, A., & Hartmann, A. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604441 · Cited by 21 · see citing works

Targeting p63 Upregulation Abrogates Resistance to MAPK Inhibitors in Melanoma

Patel, A. A., García, L. F., Mannella, V., Gammon, L., Borg, T., Maffucci, T., Scatolini, M., Chiorino, G., Vergani, E., Rodolfo, M., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-3230 · Cited by 21 · see citing works

Hyperexpression of HOXC13, located in the 12q13 chromosomal region, in well-differentiated and dedifferentiated human liposarcomas

Cantile, M., Galletta, F., Franco, R., Aquino, G., Scognamiglio, G., Marra, L., Cerrone, M., Malzone, G., MANNA, A., Apice, G., et al. (2013) · Oncology Reports · doi:10.3892/or.2013.2760 · Cited by 21 · see citing works

Co-amplification of phosphoinositide 3-kinase enhancer A and cyclin-dependent kinase 4 triggers glioblastoma progression

Qi, Q., Kang, S. S., Zhang, S., Pham, C., Fu, H., Brat, D. J., & Ye, K.-N. (2017) · Oncogene · doi:10.1038/onc.2017.67 · Cited by 19 · see citing works

Melanoma genetics: the other side

Bis, S., & Tsao, H. (2013) · Clinics in Dermatology · doi:10.1016/j.clindermatol.2012.08.003 · Cited by 17 · see citing works

Detecting copy number alterations of oncogenes in cell-free DNA to monitor treatment response in acral and mucosal melanoma

Mikoshiba, A., Ashida, A., Sakaizawa, K., Kiniwa, Y., & Okuyama, R. (2020) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2020.01.001 · Cited by 17 · see citing works

Detection of genes mutations in cerebrospinal fluid circulating tumor DNA from neoplastic meningitis patients using next generation sequencing

Zhao, Y., He, J. Y., Cui, J., Meng, Z.-Q., Zou, Y. L., Guo, X. S., Chen, X., Wang, X., Yan, L.-T., Han, W., et al. (2020) · BMC Cancer · doi:10.1186/s12885-020-07172-x · Cited by 16 · see citing works

Disrupting the PIKE-A/Akt interaction inhibits glioblastoma cell survival, migration, invasion and colony formation

Qi, Q., He, K., Liu, X., Pham, C., Meyerkord, C. L., Fu, H., & Ye, K.-N. (2012) · Oncogene · doi:10.1038/onc.2012.109 · Cited by 16 · see citing works

Differentiation of melanoma and benign nevi by fluorescence in-situ hybridization

Hossain, D., Qian, J., Adupe, J., Drewnowska, K., & Bostwick, D. G. (2011) · Melanoma Research · doi:10.1097/cmr.0b013e328347ee1d · Cited by 15 · see citing works

Loss of Keratinocytic RXRα Combined with Activated CDK4 or Oncogenic NRAS Generates UVB-Induced Melanomas via Loss of p53 and PTEN in the Tumor Microenvironment

Coleman, D. J., Chagani, S., Hyter, S. D., Sherman, A. M., Löhr, C. V., Liang, X., Ganguli‐Indra, G., & Indra, A. K. (2014) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-14-0164 · Cited by 14 · see citing works

Laryngeal Spindle Cell/Pleomorphic Lipoma: A Case Report. An In-Depth Review of the Adipocytic Tumors

Burkes, J. N., Campos, L., Williams, F. C., & Kim, R. Y. (2019) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.joms.2019.01.050 · Cited by 14 · see citing works

Next-Generation Sequencing Reveals Pathway Activations and New Routes to Targeted Therapies in Cutaneous Metastatic Melanoma

Carlson, J. A., Xavier‐Júnior, J. C. C., Tarasen, A. J., Sheehan, C. E., Otto, G. A., Miller, V. A., Stephens, P. J., Elvin, J. A., Vergilio, J., Suh, J. H., et al. (2016) · American Journal of Dermatopathology · doi:10.1097/dad.0000000000000729 · Cited by 15 · see citing works

Whole Genome and Exome Sequencing of Melanoma

Dutton‐Regester, K., & Hayward, N. K. (2012) · Advances in pharmacology · doi:10.1016/b978-0-12-397927-8.00013-0 · Cited by 13 · see citing works

The Future of Molecular Analysis in Melanoma: Diagnostics to Direct Molecularly Targeted Therapy

Akabane, H., & Sullivan, R. (2016) · American Journal of Clinical Dermatology · doi:10.1007/s40257-015-0159-z · Cited by 12 · see citing works

Clinical Significance of p16 INK4a and p53 Overexpression in Endocrine Tumors of the Gastrointestinal Tract

Li, A. F., Tsay, S., Liang, W.-Y., Li, W.-Y., & Chen, J.-Y. (2006) · American Journal of Clinical Pathology · doi:10.1309/5x6w-byj3-u94e-eknn · Cited by 12 · see citing works

Cyclin-dependent kinase 4 overexpression is mostly independent of gene amplification and constitutes an independent prognosticator for nasopharyngeal carcinoma

Chen, T., Lee, S., Lin, L., Lin, C., Chang, K., & Li, C. (2014) · Tumor Biology · doi:10.1007/s13277-014-1884-2 · Cited by 11 · see citing works

Epigenetic Contribution of High-Mobility Group A Proteins to Stem Cell Properties

Giancotti, V., Bergamin, N., Cataldi, P., & Rizzi, C. (2018) · International Journal of Cell Biology · doi:10.1155/2018/3698078 · Cited by 11 · see citing works

The relationship between MDM2 expression and tumor thickness and invasion in primary cutaneous malignant melanoma.

Rajabi, P., Karimian, P., & Heidarpour, M. (2012) · Europe PMC (PubMed Central) · Cited by 11 · see citing works

Phosphoinositide-3-Kinase Enhancers, PIKEs: Their Biological Functions and Roles in Cancer.

Jia, W., Feng, Y. I., Sanders, A. J., Davies, E. L., & Jiang, W. G. (2016) · PubMed · Cited by 11 · see citing works

Distinct gene mutation profiles among multiple and single primary lung adenocarcinoma

Wang, Y., Wang, G., Zheng, H., Liu, J., Ma, G., Huang, G., Song, Q., & Du, J. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1014997 · Cited by 10 · see citing works

Soft Tissue Sarcomas with Chromosomal Alterations in the 12q13-15 Region: Differential Diagnosis and Therapeutic Implications

Lavernia, J., Claramunt, R., Romero, I., López‐Guerrero, J. A., Llombart-Bosch, A., & Machado, I. (2024) · Cancers · doi:10.3390/cancers16020432 · Cited by 10 · see citing works

Overexpression of Tetraspanin31 contributes to malignant potential and poor outcomes in gastric cancer

Takashima, Y., Komatsu, S., Ohashi, T., Kiuchi, J., Kamiya, H., Shimizu, H., Arita, T., Konishi, H., Shiozaki, A., Kubota, T., et al. (2022) · Cancer Science · doi:10.1111/cas.15342 · Cited by 10 · see citing works

Looking for Sunshine: Genetic Predisposition to Sun Seeking in 265,000 Individuals of European Ancestry

Sanna, M., Li, X., Visconti, A., Freidin, M. B., Sacco, C., Ribero, S., Hysi, P. G., Bataille, V. A., Han, J., & Falchi, M. (2020) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2020.08.014 · Cited by 12 · see citing works

CDK4 Amplification in Esophageal Squamous Cell Carcinoma Associated With Better Patient Outcome

Huang, J., Wang, X., Zhang, X., Chen, W., Luan, L., Song, Q., Wang, H., Liu, J., Xu, L., Xu, Y., et al. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.616110 · Cited by 10 · see citing works

KGF Promotes Paracrine Activation of the SCF/c-KIT Axis from Human Keratinocytes to Melanoma Cells

Belleudi, F., Cardinali, G., Kovacs, D., Picardo, M., & Torrisi, M. R. (2010) · Translational Oncology · doi:10.1593/tlo.09196 · Cited by 10 · see citing works

High-Resolution Copy Number Patterns From Clinically Relevant FFPE Material

Filia, A., Droop, A., Harland, M., Thygesen, H. H., Randerson‐Moor, J. A., Snowden, H. H., Taylor, C., Diaz, J. M. S., Poźniak, J., Nsengimana, J., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-45210-2 · Cited by 9 · see citing works

Untitled work

Berner (1996) · doi:10.1002/(sici)1098-2264(199612)17:4

Mapping of amplification units in the q13-14 region of chromosome 12 in human sarcomas: some amplica do not include MDM2.

Forus, A., Flørenes, V. A., Mælandsmo, G. M., Meltzer, P. S., Fodstad, Ø., & Myklebost, O. (1993) · PubMed · Cited by 138 · see citing works

Characterization of candidate gene copy number alterations in the 11q13 region along with BRAF and NRAS mutations in human melanoma

Lázár, V., Ecsedi, S., Szöllősi, A. G., Tóth, R., Vízkeleti, L., Rákosy, Z., Bégány, Á., Ádány, R., & Balázs, M. (2009) · Modern Pathology · doi:10.1038/modpathol.2009.109 · Cited by 43 · see citing works

12q13–14 amplica in human sarcomas without MDM2 include CDK4, SAS and GADD153/CHOP

Forus, A., Flørenes, V. A., Mælandsmo, G. M., Meltzer, P. S., Fodstad, Ø., & Myklebost, O. (1994) · Cancer Genetics and Cytogenetics · doi:10.1016/0165-4608(94)90436-7 · Cited by 3 · see citing works

CDK4 gene copy number increase and concurrent genetic changes in acral melanoma of a Chinese cohort

Yang, L., Liu, Y., Guo, R., Du, J., Liu, L., Liu, X., Zhao, J., Fang, S., Zhang, X., & Su, J. (2024) · Pathology · doi:10.1016/j.pathol.2024.06.012 · Cited by 2 · see citing works